Delphine Boche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5212072/publications.pdf

Version: 2024-02-01

92 papers 7,297 citations

39 h-index 83 g-index

104 all docs

 $\begin{array}{c} 104 \\ \\ \text{docs citations} \end{array}$

104 times ranked 8873 citing authors

#	Article	IF	CITATIONS
1	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 360-376.	0.8	46
2	BRAIN UK: Accessing NHS tissue archives for neuroscience research. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	9
3	Histopathological correlates of haemorrhagic lesions on <i>ex vivo</i> magnetic resonance imaging in immunized Alzheimer's disease cases. Brain Communications, 2022, 4, fcac021.	3.3	7
4	Microglia and Astrocyte Function and Communication: What Do We Know in Humans?. Frontiers in Neuroscience, 2022, 16, 824888.	2.8	39
5	Iron Deposition in the Brain After Aneurysmal Subarachnoid Hemorrhage. Stroke, 2022, 53, 1633-1642.	2.0	28
6	Inflammation in dementia with Lewy bodies. Neurobiology of Disease, 2022, 168, 105698.	4.4	26
7	Combination Therapy in Alzheimer's Disease: Is It Time?. Journal of Alzheimer's Disease, 2022, , 1-17.	2.6	4
8	Review: Microglia in motor neuron disease. Neuropathology and Applied Neurobiology, 2021, 47, 179-197.	3.2	20
9	Microglial contribution to synaptic uptake in the prefrontal cortex in schizophrenia. Neuropathology and Applied Neurobiology, 2021, 47, 346-351.	3.2	7
10	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain, 2021, 144, 724-745.	7.6	19
11	Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer's disease. Brain, 2021, 144, 1869-1883.	7.6	32
12	Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: $\text{ILâ}\in \hat{\mathbf{l}}^2$ drives amplified responses in primed astrocytes and neuronal network dysfunction. Alzheimer's and Dementia, 2021, 17, 1735-1755.	0.8	87
13	Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage. Stroke, 2021, 52, 3613-3623.	2.0	19
14	Microglial morphology in Alzheimer's disease and after Aβ immunotherapy. Scientific Reports, 2021, 11, 15955.	3.3	43
15	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	2.6	52
16	Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study. Brain, Behavior, and Immunity, 2021, 97, 319-327.	4.1	24
17	Molecular Investigation of the Unfolded Protein Response in Select Human Tauopathies. Journal of Alzheimer's Disease Reports, 2021, 5, 1-15.	2.2	2
18	Clearance of interstitial fluid (ISF) and CSF (CLIC) groupâ€"part of Vascular Professional Interest Area (PIA). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12053.	2.4	53

#	Article	IF	Citations
19	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. Translational Psychiatry, 2020, 10, 267.	4.8	30
20	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1219-1226.	1.9	17
21	Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology, 2020, 46, 623-640.	3.2	20
22	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2831-2847.	6.4	45
23	Rapid neuroinflammatory changes in human acute intracerebral hemorrhage. Annals of Clinical and Translational Neurology, 2019, 6, 1465-1479.	3.7	36
24	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	6.4	49
25	Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer's Disease. Cells, 2019, 8, 639.	4.1	93
26	Microglial motility in Alzheimer's disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathologica Communications, 2019, 7, 174.	5.2	35
27	AÎ ² 43 in human Alzheimer's disease: effects of active AÎ ² 42 immunization. Acta Neuropathologica Communications, 2019, 7, 141.	5.2	20
28	Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Brain, 2019, 142, 2113-2126.	7.6	127
29	A novel method to visualise the threeâ€dimensional organisation of the human cerebral cortical vasculature. Journal of Anatomy, 2018, 232, 1025-1030.	1.5	8
30	Innate immunity in Alzheimer's disease: the relevance of animal models?. Journal of Neural Transmission, 2018, 125, 827-846.	2.8	16
31	Downregulated apoptosis and autophagy after antiâ€Aβ immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	4.1	24
32	TREM2 expression in the human brain: a marker of monocyte recruitment?. Brain Pathology, 2018, 28, 595-602.	4.1	55
33	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 88.	5.2	52
34	PKR modulates abnormal brain signaling in experimental obesity. PLoS ONE, 2018, 13, e0196983.	2.5	8
35	Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 3.	5.2	69
36	Miniâ€symposium: Role of the inflammasome in brain pathogenesis: a potential therapeutic target? ― introduction. Brain Pathology, 2017, 27, 190-191.	4.1	1

#	Article	IF	Citations
37	What do we know about the inflammasome in humans?. Brain Pathology, 2017, 27, 192-204.	4.1	35
38	Effect of antiâ€cancer drugs on microglia in patientâ€derived breast cancer xenografted mouse models. Neuropathology, 2017, 37, 91-93.	1.2	4
39	Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?. Brain Pathology, 2017, 27, 266-275.	4.1	22
40	[ECâ€02–02]: THE NEUROINFLAMMATORY PROFILE IN ALZHEIMER's DISEASE: EFFECT OF SYSTEMIC INFECTION Alzheimer's and Dementia, 2017, 13, P546.	N. _{0.8}	0
41	Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. Frontiers in Psychiatry, 2017, 8, 238.	2.6	114
42	Amyloid: Vascular and Parenchymal ☆., 2017,,.		2
43	P3â€106: Acute Systemic Infection and FCΓ Receptors in Alzheimer's Disease: An Immunosuppressive Environment. Alzheimer's and Dementia, 2016, 12, P859.	0.8	O
44	Microglial immunophenotype in dementia with Alzheimer's pathology. Journal of Neuroinflammation, 2016, 13, 135.	7.2	159
45	Heme–Hemopexin Scavenging Is Active in the Brain and Associates With Outcome After Subarachnoid Hemorrhage. Stroke, 2016, 47, 872-876.	2.0	46
46	Microglia regulate hippocampal neurogenesis during chronic neurodegeneration. Brain, Behavior, and Immunity, 2016, 55, 179-190.	4.1	90
47	Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 42.	6.2	99
48	F1-02-03: Microglia heterogeneity in the human Alzheimer's brain., 2015, 11, P117-P117.		0
49	Novel association between microglia and stem cells in human gliomas: A contributor to tumour proliferation?. Journal of Pathology: Clinical Research, 2015, 1, 67-75.	3.0	6
50	Effect of amyloidâ $\in \hat{l}^2$ ($<$ scp $>$ A $<$ /scp $>$ \hat{l}^2) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase $<$ scp $>$ (GSK $<$ /scp $>$)â $\in \hat{s}$ \hat{l}^2 . Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	3.2	17
51	Effect of active $A < i > \hat{l}^2 < i > immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.$	4.5	31
52	Haemoglobin Scavenging After Subarachnoid Haemorrhage. Acta Neurochirurgica Supplementum, 2015, 120, 51-54.	1.0	15
53	Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathologica, 2014, 128, 777-789.	7.7	44
54	P.1.d.001 Multi-immunostaining for microglial activation in schizophrenia. European Neuropsychopharmacology, 2014, 24, S188-S189.	0.7	0

#	Article	IF	CITATIONS
55	Rat astrocytic tumour cells are associated with an antiâ€inflammatory microglial phenotype in an organotypic model. Neuropathology and Applied Neurobiology, 2013, 39, 243-255.	3.2	4
56	Neuroinflammation in ageing and in neurodegenerative disease. Neuropathology and Applied Neurobiology, 2013, 39, 1-2.	3.2	9
57	Review: Activation patterns of microglia and their identification in the human brain. Neuropathology and Applied Neurobiology, 2013, 39, 3-18.	3.2	792
58	Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain, 2013, 136, 2677-2696.	7.6	234
59	Investigating Interventions in Alzheimer's Disease with Computer Simulation Models. PLoS ONE, 2013, 8, e73631.	2.5	28
60	The intrathecal CD163â€haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhage. Journal of Neurochemistry, 2012, 121, 785-792.	3.9	98
61	Microglial alterations in human Alzheimer's disease following A \hat{l}^2 42 immunization. Neuropathology and Applied Neurobiology, 2011, 37, 513-524.	3.2	88
62	Synapses and Alzheimers's Disease: Effect of Immunotherapy?. , 2011, , 269-287.		0
63	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Acta Neuropathologica, 2010, 120, 13-20.	7.7	80
64	Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathologica, 2010, 120, 369-384.	7.7	122
65	Are we getting to grips with Alzheimer's disease at last?. Brain, 2010, 133, 1297-1299.	7.6	7
66	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	6.2	189
67	Amyloid: Vascular and Parenchymal. , 2009, , 355-362.		2
68	Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathologica, 2009, 118, 87-102.	7.7	256
69	Long-term effects of $\widehat{Al^2}42$ immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	13.7	1,333
70	Amyloid-β vaccination for Alzheimer's dementia – Authors' reply. Lancet, The, 2008, 372, 1381-1382.	13.7	11
71	Consequence of $\hat{Al^2}$ immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131, 3299-3310.	7.6	283
72	A \hat{l}^2 Species Removal After A \hat{l}^2 sub>42 < /sub>1 mmunization. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1040-1048.	1.7	260

#	Article	IF	Citations
73	Immunotherapy for Alzheimer's Disease and Other Dementias. Clinical Neuropharmacology, 2006, 29, 22-27.	0.7	7
74	ISNI 2006 Abstracts. Journal of Neuroimmunology, 2006, 178, 1-271.	2.3	54
75	TGF \hat{l}^21 regulates the inflammatory response during chronic neurodegeneration. Neurobiology of Disease, 2006, 22, 638-650.	4.4	88
76	Immunotherapy for Alzheimer's disease and other dementias. Current Opinion in Neurology, 2005, 18, 720-725.	3.6	17
77	MCP-1 and murine prion disease: Separation of early behavioural dysfunction from overt clinical disease. Neurobiology of Disease, 2005, 20, 283-295.	4.4	62
78	Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia, 2005, 49, 375-384.	4.9	160
79	Comparison of Inflammatory and Acute-Phase Responses in the Brain and Peripheral Organs of the ME7 Model of Prion Disease. Journal of Virology, 2005, 79, 5174-5184.	3.4	55
80	Neuropathologically distinct prion strains give rise to similar temporal profiles of behavioral deficits. Neurobiology of Disease, 2005, 18, 258-269.	4.4	74
81	Neuropil and neuronal changes in hippocampal NADPH-diaphorase histochemistry in the ME7 model of murine prion disease. Neuropathology and Applied Neurobiology, 2004, 30, 292-303.	3.2	11
82	Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. European Journal of Neuroscience, 2003, 17, 2147-2155.	2.6	243
83	Transforming Growth Factor- \hat{l}^21 -Mediated Neuroprotection against Excitotoxic Injury (i>in Vivo $\langle i\rangle$. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1174-1182.	4.3	114
84	Atypical inflammation in the central nervous system in prion disease. Current Opinion in Neurology, 2002, 15, 349-354.	3.6	159
85	Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathology and Applied Neurobiology, 2002, 28, 107-119.	3.2	73
86	Progressive multifocal leukoencephalopathy and oligodendroglioma in a monkey co-infected by simian immunodeficiency virus and simian virus 40. Acta Neuropathologica, 2000, 100, 332-336.	7.7	16
87	Viral load and neuropathology in the SIV model. Journal of NeuroVirology, 1999, 5, 232-240.	2.1	40
88	Dissociation between viral load and neuropathology in the SIV model: Key role of glial cells. Journal of Neuroimmunology, 1998, 90, 63.	2.3	0
89	Neuropathology of Early HIVâ€1 Infection. Brain Pathology, 1996, 6, 1-12.	4.1	266
90	Virus load and neuropathology in the FIV model. Journal of NeuroVirology, 1996, 2, 377-387.	2.1	30

DELPHINE BOCHE

#	Article	IF	CITATIONS
91	Low susceptibility of resident microglia to simian immunodeficiency virus replication during the early stages of infection. Neuropathology and Applied Neurobiology, 1995, 21, 535-539.	3.2	10
92	Differential perivascular microglial activation in the deep white matter in vascular dementia developed postâ€stroke. Brain Pathology, 0, , .	4.1	6